Morgan Stanley Downgrades ResMed (RMD) to Equalweight
More News related to RMD
- Notable Analyst rating Changes for 02/05: RMD, WFR, ALKS, SFN, BEBE Upgraded; FWD, EGOV, LEAP, COH, CIEN Downgraded
- Morning Movers 2/5: ARG, KOOL, PWER, BEBE, END Higher; PFWD, EGOV, INPH, N, PTEC Lower
- Wells Fargo Upgrades ResMed (RMD) to Market Perform; Shares Fairly Valued
- After-Hours Movers 2/4: PWER, OPTR, PTIX, HA, TSYS Higher; PWAV, TTMI, MFLX, SNCR, BMI Lower
- ResMed (RMD) Tops Q2 EPS by 5c
More News related to Downgrades
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
Morgan Stanley downgrades ResMed (NYSE: RMD) from Overweight to Equalweight.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
Related Categories
DowngradesStocks Mentioned
-0.57Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
